About Akero Therapeutics
Akero Therapeutics is a clinical-stage biopharmaceutical company revolutionizing the treatment of serious metabolic diseases. Our lead program, efruxifermin (EFX), targets metabolic dysfunction-associated steatohepatitis (MASH), a condition with significant unmet medical needs. We leverage cutting-edge scientific approaches to develop transformative therapies, restoring metabolic balance and halting disease progression. Our team combines diverse expertise and a collaborative spirit to achieve ambitious goals. Akero's commitment to innovation is reflected in our work on AKR-001, a long-acting FGF21 protein, building upon two decades of research.
We utilize a robust technology stack, including tools like WordPress, Google Analytics, and Google Tag Manager, supporting a streamlined workflow. Our engineering culture fosters independent thinking and creative problem-solving, while we maintain high standards for quality and regulatory compliance (cGMP and GLP). We pride ourselves on a supportive and inclusive environment that enables growth and success.
Akero is a rapidly growing company with a significant market presence in the NASH treatment space, backed by substantial funding and a public listing on NASDAQ. As a publicly traded company, Akero operates with transparency and integrity, making it an exciting and rewarding place to build your career. We offer competitive compensation and benefits, with many positions open for remote work.
We are a dynamic, driven team with a passion for making a difference in the lives of patients. Join us to transform the future of metabolic disease treatment.